Showing results (91-100 of 566) with videos related to
Sort By:
Pageof 57
Rheumatic Diseases Clinics of North America|August 9, 2005
Does mixed connective tissue disease exist? YesMartin Aringer, Günter Steiner, Josef S SmolenHealth and Quality of Life Outcomes|March 7, 2014
Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholdsVibeke Strand, Mark Kosinski, Ari Gnanasakthy, et al.Drug Safety|June 13, 2021
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019Juliana Setyawan, Nassir Azimi, Vibeke Strand, et al.The Journal of Rheumatology|January 17, 2019
The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy AnalysisMihir D Wechalekar, Aurélie Najm, Douglas J Veale, et al.Journal of Managed Care & Specialty Pharmacy|March 27, 2018
Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid ArthritisVibeke Strand, Namita Tundia, Yan Song, et al.Lupus Science & Medicine|June 28, 2020
Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic reviewVibeke Strand, Lee S Simon, Alexa Simon Meara, et al.RMD Open|May 14, 2016
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritisRoy Fleischmann, Vibeke Strand, Bethanie Wilkinson, et al.Pharmacoeconomics|January 31, 2002
Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trialAndreas Maetzel, Vibeke Strand, Peter Tugwell, et al.Arthritis and Rheumatism|January 11, 2003
Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAndreas Maetzel, Vibeke Strand, Peter Tugwell, et al.Patient Related Outcome Measures|January 23, 2019
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studiesElvira Bangert, Laura Wakani, Mehveen Merchant, et al.Pageof 57